SL
Siren LLC Portfolio holdings
AUM
$1.93B
This Quarter Return
+22.44%
1 Year Return
+118.08%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$2B
AUM Growth
–
Cap. Flow
+$2B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
41.3%
Holding
110
New
109
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Kymera Therapeutics
KYMR
|
$141M |
| 2 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$126M |
| 3 |
Scholar Rock
SRRK
|
$90.2M |
| 4 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$78.3M |
| 5 |
argenx
ARGX
|
$77.9M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 93.6% |
| 2 | Technology | 2.88% |
| 3 | Communication Services | 1.83% |
| 4 | Consumer Discretionary | 0.77% |
| 5 | Real Estate | 0.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Kymera Therapeutics
KYMR
$2.95B
| $141M | 7.03% | +2,969,733 | New | +$141M |
|
|
ONC
2
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $126M | 6.32% | +563,314 | New | +$126M |
|
|
3
Scholar Rock
SRRK
$3.14B
| $90.2M | 4.51% | +11,259,438 | New | +$90.2M |
|
|
BCAX
4
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $78.3M | 3.91% | +3,072,827 | New | +$78.3M |
|
|
5
argenx
ARGX
$43.6B
| $77.9M | 3.89% | +143,647 | New | +$77.9M |
|
6
Crinetics Pharmaceuticals
CRNX
$2.92B
| $66.9M | 3.35% | +1,309,652 | New | +$66.9M |
|
7
Avidity Biosciences
RNA
$5.99B
| $66.2M | 3.31% | +1,440,736 | New | +$66.2M |
|
8
Apellis Pharmaceuticals
APLS
$3.48B
| $62.5M | 3.12% | +2,167,224 | New | +$62.5M |
|
9
Lexicon Pharmaceuticals
LXRX
$400M
| $61.1M | 3.05% | +38,918,903 | New | +$61.1M |
|
|
IGMS
10
DELISTED
IGM Biosciences
IGMS
| $55.1M | 2.75% | +3,330,422 | New | +$55.1M |
|
|
CNTA
11
Centessa Pharmaceuticals
CNTA
$2.25B
| $52.1M | 2.6% | +3,258,677 | New | +$52.1M |
|
12
Ascendis Pharma
ASND
$11.8B
| $51.9M | 2.6% | +347,921 | New | +$51.9M |
|
|
SLN
13
Silence Therapeutics
SLN
$227M
| $51.5M | 2.57% | +2,831,770 | New | +$51.5M |
|
14
Arrowhead Research
ARWR
$3.05B
| $47.6M | 2.38% | +2,458,778 | New | +$47.6M |
|
15
Wave Life Sciences
WVE
$1.53B
| $46.9M | 2.35% | +5,721,172 | New | +$46.9M |
|
|
SWTX
16
DELISTED
SpringWorks Therapeutics
SWTX
| $44.1M | 2.21% | +1,377,701 | New | +$44.1M |
|
17
Dyne Therapeutics
DYN
$1.92B
| $40.8M | 2.04% | +1,134,664 | New | +$40.8M |
|
18
Vera Therapeutics
VERA
$1.38B
| $37M | 1.85% | +837,928 | New | +$37M |
|
19
Neumora Therapeutics
NMRA
$280M
| $34.4M | 1.72% | +2,606,571 | New | +$34.4M |
|
20
Vaxcyte
PCVX
$4B
| $34.3M | 1.71% | +299,991 | New | +$34.3M |
|
21
Revolution Medicines
RVMD
$7.1B
| $34.2M | 1.71% | +753,601 | New | +$34.2M |
|
22
Merus
MRUS
$4.98B
| $34.1M | 1.7% | +682,201 | New | +$34.1M |
|
23
Taboola.com
TBLA
$991M
| $33.5M | 1.67% | +9,969,495 | New | +$33.5M |
|
|
LBPH
24
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $30.1M | 1.51% | +903,227 | New | +$30.1M |
|
25
Xenon Pharmaceuticals
XENE
$2.98B
| $29.3M | 1.46% | +743,769 | New | +$29.3M |
|